Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Receivables (2016 - 2025)

Historic Receivables for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to $1.2 billion.

  • Dexcom's Receivables rose 2091.06% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year increase of 2091.06%. This contributed to the annual value of $1.2 billion for FY2025, which is 2091.06% up from last year.
  • As of Q4 2025, Dexcom's Receivables stood at $1.2 billion, which was up 2091.06% from $1.1 billion recorded in Q3 2025.
  • In the past 5 years, Dexcom's Receivables ranged from a high of $1.4 billion in Q2 2025 and a low of $455.6 million during Q1 2021
  • In the last 5 years, Dexcom's Receivables had a median value of $777.2 million in 2023 and averaged $827.0 million.
  • In the last 5 years, Dexcom's Receivables surged by 6285.81% in 2021 and then surged by 392.45% in 2024.
  • Quarter analysis of 5 years shows Dexcom's Receivables stood at $529.3 million in 2021, then surged by 37.84% to $729.6 million in 2022, then soared by 35.86% to $991.2 million in 2023, then grew by 3.92% to $1.0 billion in 2024, then increased by 20.91% to $1.2 billion in 2025.
  • Its Receivables stands at $1.2 billion for Q4 2025, versus $1.1 billion for Q3 2025 and $1.4 billion for Q2 2025.